Recent advancements in nanotechnology based drug delivery for the management of cardiovascular disease

Curr Probl Cardiol. 2024 Apr;49(4):102396. doi: 10.1016/j.cpcardiol.2024.102396. Epub 2024 Jan 22.

Abstract

Cardiovascular diseases (CVDs) constitute a predominant cause of both global mortality and morbidity. To address the challenges in the early diagnosis and management of CVDs, there is growing interest in the field of nanotechnology and nanomaterials to develop innovative diagnostic and therapeutic approaches. This review focuses on the recent advancements in nanotechnology-based diagnostic techniques, including cardiac immunoassays (CIA), cardiac circulating biomarkers, cardiac exosomal biomarkers, and molecular Imaging (MOI). Moreover, the article delves into the exciting developments in nanoparticles (NPs), biomimetic NPs, nanofibers, nanogels, and nanopatchs for cardiovascular applications. And discuss how these nanoscale technologies can improve the precision, sensitivity, and speed of CVD diagnosis and management. While highlighting their vast potential, we also address the limitations and challenges that must be overcome to harness these innovations successfully. Furthermore, this review focuses on the emerging opportunities for personalized and effective cardiovascular care through the integration of nanotechnology, ultimately aiming to reduce the global burden of CVDs.

Keywords: Cardiovascular diseases; Diagnosis; Management; Nanomaterials; Nanotechnology.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / drug therapy
  • Humans
  • Nanotechnology

Substances

  • Biomarkers